69 research outputs found

    Potassium/calcium/nickel oxide catalysts for the oxidative coupling of methane

    Get PDF
    A series of potassium/calcium/nickel oxides were tested for the oxidative coupling of methane (OCM) at 843–943 K and water addition to the feed at 0–66 mol-%. The K/Ni ratios varied from 0.0–0.6 and Ca/Ni from 0.0–11; catalysts with no nickel were also tested. At least 10% water in the feed and temperatures lower than ca. 940 K were necessary to keep nickel-containing catalysts from converting to purely steam reforming/combustion behavior. Catalysts of low (less than 4) Ca/Ni were the most active, with a maximum C2 selectivity, which increased with temperature, of 37% at 11% C2 yield (28% water in feed, 933 K). Catalysts of high (4–11 ) Ca/Ni ratio were less active, with a maximum C2 selectivity of 32% at 7.1% C2 yield (43% water in feed, 923 K). Previous claims of higher selectivities for similar catalysts could not be reproduced except at short times on stream, in the absence of substantial carbonate buildup. These transient selectivities were not associated with the nickel-containing phase. At steady state, both C2 yields and selectivities increased with respect to the water content of the feed, while decreasing with C1/O2 ratio. The latter behavior is unusual and may be related to the reduction of higher valent potassium/calcium/nickel oxide. The existence of such material as an active phase for OCM was suggested by the results of X-ray diffraction, differentional scanning calorimetry, temperature-programmed reduction, and laser Raman spectroscopic characterizations of fresh and used catalysts

    Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Mutations in the mitochondrial genome (mtgenome) have been associated with many disorders, including breast cancer. Nipple aspirate fluid (NAF) from symptomatic women could potentially serve as a minimally invasive sample for breast cancer screening by detecting somatic mutations in this biofluid. This study is aimed at 1) demonstrating the feasibility of NAF recovery from symptomatic women, 2) examining the feasibility of sequencing the entire mitochondrial genome from NAF samples, 3) cross validation of the Human mitochondrial resequencing array 2.0 (MCv2), and 4) assessing the somatic mtDNA mutation rate in benign breast diseases as a potential tool for monitoring early somatic mutations associated with breast cancer.</p> <p>Methods</p> <p>NAF and blood were obtained from women with symptomatic benign breast conditions, and we successfully assessed the mutation load in the entire mitochondrial genome of 19 of these women. DNA extracts from NAF were sequenced using the mitochondrial resequencing array MCv2 and by capillary electrophoresis (CE) methods as a quality comparison. Sequencing was performed independently at two institutions and the results compared. The germline mtDNA sequence determined using DNA isolated from the patient's blood (control) was compared to the mutations present in cellular mtDNA recovered from patient's NAF.</p> <p>Results</p> <p>From the cohort of 28 women recruited for this study, NAF was successfully recovered from 23 participants (82%). Twenty two (96%) of the women produced fluids from both breasts. Twenty NAF samples and corresponding blood were chosen for this study. Except for one NAF sample, the whole mtgenome was successfully amplified using a single primer pair, or three pairs of overlapping primers. Comparison of MCv2 data from the two institutions demonstrates 99.200% concordance. Moreover, MCv2 data was 99.999% identical to CE sequencing, indicating that MCv2 is a reliable method to rapidly sequence the entire mtgenome. Four NAF samples contained somatic mutations.</p> <p>Conclusion</p> <p>We have demonstrated that NAF is a suitable material for mtDNA sequence analysis using the rapid and reliable MCv2. Somatic mtDNA mutations present in NAF of women with benign breast diseases could potentially be used as risk factors for progression to breast cancer, but this will require a much larger study with clinical follow up.</p

    Finishing the euchromatic sequence of the human genome

    Get PDF
    The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

    Oxidation catalysis in a supercritical fluid medium

    No full text

    Stable Nickel-Containing Catalysts for the Oxidative Coupling of Methane

    Get PDF
    A new catalyst based on the K/Ca/Ni oxide system has been developed for the oxidative coupling of methane at <700°C. It is capable of up to 70% selectivity to C2+ hydrocarbons at complete O2 conversion (CH4/O2 RATIO = 2.5) if 35% water is present in the feed. Unlike previous materials of this type, the present catalyst is stable at the conditions of its maximum yield to C2+ products and is not poisoned by CO2. On the contrary, it appears as if CO2 promotes formation of a selective hydroxycarbonate phase which develops under reaction conditions
    • …
    corecore